Add this topic to your myFT Digest for news straight to your inbox
Immunotherapy is a crowded market but previous venture Kite made shareholders a fortune
Mainstream asset managers have begun using big data and machine learning
Near-$12bn purchase of Kite predicated on promising but expensive Car-T therapy
Biotech M&A is about market size bets, not synergies
Deal validates Kite’s Car-T treatment for cancer by re-engineering white blood cells
Purchase add cutting edge anti-cancer technology to its portfolio
Cell therapies could win regulatory approval but can the process ever be economically viable to satisfy investors?
Recent deaths raise fears that a treatment for blood cancers is being brought to market too quickly
Trials impress though safety and price questions remain
Modifying white blood cells to fight tumours is saving lives but there is still much to prove
One business, Celyad, is making a name for itself in a promising area of medicine
Big pharma groups pay higher charges for access to most promising molecules
International Edition